ClinicalTrials.gg

Program

NWRD08

A development code. Also written as “NWRD08 administered by electroporation”.

Its studies are mostly in Squamous Intraepithelial Lesions, led by Newish Biotech (Wuxi).

Furthest: phase 2, since Sep 1, 20253 company-led studies, 2 open or runningNext primary completion: May 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Newish Biotech (Wuxi)32 open or runningphase 2since Sep 1, 2025May 23, 2023May 30, 2027phase 2 · NCT07175662

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 23, 2023First study: no phase study in HSIL of CervixFirst studyNCT05905354 · 12 planned · China
  2. Feb 18, 2024Phase 1 study in Squamous Intraepithelial LesionsNCT06276101 · 9 enrolled · China
  3. Sep 1, 2025Phase 2 study in Squamous Intraepithelial LesionsNCT07175662 · 150 planned · China

Ahead

  1. May 30, 2027Primary completion: phase 2 study in Squamous Intraepithelial LesionsNCT07175662

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07175662Squamous Intraepithelial Lesions · China2RecruitingMay 30, 2027150
NCT06276101Squamous Intraepithelial Lesions · China1CompletedFeb 19, 20259
NCT05905354HSIL of Cervix · China–RecruitingJun 30, 202412

How it is read

Names in the registry

  • “NWRD08 administered by electroporation”, 2 entries
  • “NWRD08”, 1 entry

Codes read as this program: NWRD08.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.